Background/Aims: The targeted therapy for triple-negative breast cancer (TNBC) is still challenging due to poor understanding on its molecular etiology. The androgen receptor (AR) has recently emerged as a prognostic and treatment-predictive marker in breast cancer. However, the role of AR in TNBC remained elusive. Methods: Immunohistochemistry (IHC) was used to detect AR and G-protein coupled estrogen receptor (GPER) expression in tissue microarrays of 165 TNBC patients. Microarray analysis of mRNAs was performed to identify downstream regulators of AR. TNBC cells were cultured with dihydrotestosterone (DHT) alone or in combination with AR knockdown performed with AR shRNA. Cell viability and colony formation were assessed. Western blotting and qRT-PCR were used to examine protein and mRNA expression, respectively. The potential mechanism of AR-mediated GPER suppression was identified by Chromatin immunoprecipitation (ChIP) assay. AR and GPER expressions were also assessed in nude mouse xenografts by IHC. Results: IHC staining showed that the expression of AR was positively associated with tumor size, lymph node metastasis and highgrade tumor in TNBC patients. AR activation triggered by DHT suppressed GPER expression, to promote cell growth of TNBC. G-1, a GPER agonist, inhibited DHT-stimulated proliferation. Further experiments illustrated that AR suppressed GPER activation via binding directly to the promoter of GPER. Moreover, a negative correlation between AR and GPER was observed in MDA-MB-231 tumor cell xenografts and TNBC patient samples. Conclusions: The suppression of GPER via AR may be involved in the positive actions towards the TNBC progression, making it a promising therapeutic target for TNBC treatment.
Immunohistochemistry (IHC) staining and Evaluation
Slides were deparaffinized in a series of xylenes and ethanols. Heat-mediated antigen retrieval was fulfilled with citrate buffer (BioGenex Laboratories, San Ramon, CA). Antibodies used for Immunohistochemistry staining included: rabbit anti-GPER antibody (BA3433-2, 1:50, Boster), and rabbit anti-AR antibody (ab74272, 1:350, Abcam). Immunostained sections were scanned using a microscope (Aiovert 200, Carl Zeiss). According to previous researches [19, 20] , a cut-off of 10% -those below this being classified as negative and those above being positive -was used in our assessment of AR and GPER expression. All the assessments were done in a blinded manner and determined independently by two senior pathologists.
Microarray analysis
MDA-MB-231 and Hs578T cells were treated with 100 n M of DHT for 48 hours. The total RNA was extracted from treated or untreated TNBC cells and mRNA was purified from total RNA after removal of rRNA (mRNA-ONLY™ Eukaryotic mRNA Isolation Kit, Epicentre). Then, each sample was amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 3' bias utilizing a random priming method (Arraystar Flash RNA Labeling Kit, Arraystar). The labeled cRNA was then hybridized onto the Microarray v3.0 (ArrayStar). After the washing steps, the Agilent DNA Microarray Scanner (part number G2505C) was used to scan the arrays. Acquired array images were analyzed by Agilent Feature Extraction software (version 11.0.1.1). Quantile normalization and subsequent data processing were performed using The Agilent GeneSpring GX v12.1 software package (Agilent Technologies). The threshold we used to screen dysregulated mRNAs is fold-change ≥ 2.0 and a P-value ≤ 0.05.
Reagents and Cell culture
Dihydrotestosterone (DHT, Sigma) was dissolved in ethanol and rel-1-[4-(6-bromo-1, 3-benzodioxol-5-yl)-3aR,4S,5, 9bS-tetrahydro-3H-cyclopenta [c]quinolin-8-yl]-ethanone (G-1, Cayman, USA) was solubilized in dimethyl sulfoxide (DMSO). Cells were plated into 6-or 96-well dishes and treated with designated concentrations of DHT or G-1 for indicated time. TNBC cell lines MDA-MB-231 and Hs578T were purchased from the Chinese Academy of Science Committee Type Culture Collection Cell Bank (Shanghai, China). Cells were cultured in RPMI 1640 or DMEM medium (GIBCO, USA) supplemented with 10% FBS and 1% penicillin/streptomycin, and 5% insulin is added for Hs578T cells. Cell cultures were carried out in a humiditied 37°C incubator supplied with 5% CO 2 .
Plasmids and Transient Transfection
The sequences of AR short hairpin RNA (shRNA) were 5′-CACCAATGTCAACTCCAGGAT-3′, and the sequences of GPER shRNA were 5′-CGAGTTAAAGAGGAGAAGGAA-3′. The two shRNAs, the plasmid AR and negative control were all chemically synthesized by GenePharma (Shanghai, China). Cells (1 × 10 6 cells/ well) were plated in 6-well plates 24 h prior to transfection and transfected using Lipofectamine 2000 reagent (Invitrogen), according to the manufacturer's protocol. After 6 h of transfection, we replaced the transfection medium with the normal one. Cells were harvested for testing when they occupied 80% of the plate.
Cell viability assay
A total of 1 × 10 4 cells per well were seeded into 96-well plates in regular growth medium. Cells were washed once they had attached and then incubated in medium containing specific concentrations of DHT, G-1 or transfected with required plasmids for 48 h. Following addition of 20 μ L of 0.5 mg/mL dimethylthiazoldiphenyltetrazoliumbromide (MTT, Sigma-Aldrich) solution to each well, the medium was replaced with 200 μ L DMSO after 4 h and vortexed for 10 min. Absorbance was measured with a microplate reader (BIO-RAD, USA) at a test wavelength of 490 nm. Each experiment was performed in triplicate.
Colony formation assay
Cells were seeded in six-well plates at a density of 500 cells per well for approximately 24 h under standard conditions. After specific treatments, the cells then were exposed to DHT alone or in combination with G-1. After nearly two weeks of incubation, the colonies were fixed with methanol, stained with 0.5% crystal violet in absolute ethanol, and colonies with ≥50 cells were counted under a dissection microscope. These experiments were repeated at least three times.
Western blot analysis
Total protein was extracted using RIPA buffer supplemented with protease and phosphatase inhibitors according to the manufacturer's protocol. Approximately 20 μ g protein was loaded per lane and separated on a sodium dodecylsulfate-polyacrylamide gel and blotted onto nitrocellulose. Blots were blocked with 5% dry milk in tris-buffered saline/0.1% tween-20 and incubated overnight with a diluted solution of primary antibody at 4 °C, and then with incubation with a horseradish peroxidase-conjugated secondary antibody (1:5000) for 2 h. Antibodies used for western blot included: rabbit anti-GPER antibody (BA3433-2, 1:500, Boster), and rabbit anti-AR antibody (ab74272, 1:200, Abcam). Bands were normalized to GAPDH expression. Results from at least two separate experiments were analyzed.
Quantitative real-time PCR Total RNA was extracted from cells with the RNAiso Plus reagent (Takara, Japan) according to the manufacturer's protocol. Total cDNA was synthesized in a reaction mix containing 2 mg of total RNA and PrimeScript RT reagent Kit with gDNA Eraser (Takara, Japan). qRT-PCR was implemented with Step One (TM) sequence detection system (Applied Biosystems Inc, Milan, Italy) using validated primers and SYBR Premix Ex Taq II (Takara, Japan), following the manufacturer's instructions. The cycle number at threshold (Ct) was used to quantify the transcript levels of genes of interest. Primer pairs were as follows: AR, forward 5′-GGGCGAAGTAGAGCATCCT-3′ and reverse 5′-GACGACCAGATGGCTGTCATT-3′; GPER, forward 5′-AGTCGGATGTGAGGTTCAG-3′ and reverse 5′-TCTGTGTGAGGAGTGCAAG-3′; GAPDH, forward 5′-TGTTGCCATCAATGACCCCTT-3′ and reverse 5′-CTCCACGACGTACTCAGCG-3′. Assays were performed in triplicate and the results were normalized for GAPDH expression and then calculated as fold induction of RNA expression.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using Pierce Agarose ChIP Kit (Thermo) according to the manufacturer's instructions. In brief, 70% confluent MDAMB-231 cells were treated with ethanol or 100 n M DHT for 2h and then fixed in 1% formaldehyde for 15 min. Centrifugation for 5 min, and sonicate the lysate to shear the cross-linked DNA to an average length of 100-1000 bp. Remove the insoluble material by centrifugation. The immuno-cleared chromatin was immunoprecipitated with anti-AR (Ab74272, 1:200, abcam) or control IgG antibody overnight at 4°C. Reverse the cross-links by proteinase K in ChIP Elution buffer for 1.5 h at 65°C. 1 μl of each of the purified DNA was used to determine the concentration. Each sample was used as template for PCR with specific primers. 10 primer sets were designed for the GPER promoter region. Primer sequences were designed for about every 300 bp of each promoter set shown in Table 1 , as the sequences amplified Table 1 . The following sequences of primers were designed for GPER promoter in ChIP analysis. 10 primer sets of about 300 bp per primer were synthesized for the GPER promoter region. The sequences amplified by primer set 1 is the fastest from the transcription start site Cellular Physiology and Biochemistry
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by primer sets 1 is the fastest from the transcription start site. PCR products were separated on 2% agarose gels, stained with ethidium bromide and photo each.
Statistical analysis
Statistical analysis was performed with SPSS Statistics 19.0 (SPSS Inc.) and GraphPad Prism 6. Data were analyzed using one-way ANOVA or a Student's t-test. Data are presented as means ± SD of three independent experiments. The chi-square test was used for IHC data. The correlation between AR and GPER expression level was estimated using Pearson's correlation analysis. A P value of < 0.05 was considered statistically significant.
＊ P < 0.05, 
Results

Activation of AR via DHT promotes in vitro viability of TNBC
Recent studies have found that the androgen receptor (AR) is present in approximately 60-70% of all breast cancers, and in up to about 30% of patients with triple-negative breast cancer (TNBC) [21] , making it an attractive therapeutic target and, likely, a prognostic marker. In this present study, we analyzed the expression of AR in a tissue microarray of 165 TNBC tumors by IHC. Representative low-expression and high-expression AR immunostainings of TNBC samples were shown in Fig. 1A . Of the 165 tumor tissues, 59 cases (35.8%) and 106 cases (64.2%) expressed AR at high and low levels, respectively (Table 2 ). Importantly, the expression level of AR is significantly (P < 0.05) positively associated with tumor size, highgrade tumors and lymph node metastasis (Table 2) .
Thus, we investigated the roles of AR in the motility of TNBC cells. In line with our published data, which demonstrated that AR inhibitor exhibits antiproliferative effect in mesenchymal stem-like (MSL) TNBC cells [22] , we observed the positive effect of DHT, a well-known AR agonist, on cellular viability of two AR-positive MSL TNBC cells, namely MDA-MB-231 and Hs578T. We assessed the positive action of increasing concentrations of DHT at 0.1 to 100 n M on MDA-MB-231 and Hs578T cells by MTT assay. A dose-dependent enhancement of cell proliferation was observed, and it was significantly induced at the highest concentration of 100 n M (Fig. 1B) . Furthermore, we attempted to evaluate the active effects of DHT on cellular viability in different time durations. MDA-MB-231 and Hs578T cells were treated with DHT at the concentration of 100 n M and samples were collected at different time points (24, 48 , or 72 h). As shown in Fig. 1C , DHT treatment enhanced cellular proliferation at different time points in the two cell lines mentioned above. Moreover, we determined the expression of AR in MDA-MB-231 and Hs578T, treated with DHT by western blot analysis. As shown in Fig. 1D , DHT treatment resulted in a significant increase of AR protein expression in the two TNBC cells. Additionally, qRT-PCR analysis showed that DHT treatment noticeably upregulated AR transcript levels in both MDA-MB-231 and Hs578T cells (Fig. 1E) . Furthermore, we knocked down AR in the presence of DHT and found that AR deficiency significantly blocked DHT-induced cell proliferation in the two TNBC cells (Fig. 1F) . Taken together, these data manifest that AR activation via DHT promotes cell proliferation of TNBC. 
GPER expression is inhibited by DHT
To identify the targeted genes regulated by AR and involved in the process of ARstimulated proliferation, we treated MDA-MB-231 and Hs578T cells with vehicle or DHT at 100 n M for 48 h. We then conducted microarray analysis to compare mRNA expression levels between DHT treated and untreated cells, and found 23 remarkably upregulated and 48 remarkably downregulated mRNAs in both two cell lines in DHT treated group compared with control group (Fig. 2A) . The seven-transmembrane G protein-coupled estrogen receptor (GPER, also known as GPR30), a member of G protein-coupled receptor (GPCR), has been reported to be activated by estrogen to modulate the progression of various hormone-responsive tumors including ER positive breast cancer [23] . Intriguingly, recent 
studies indicated that GPER was also greatly expressed in TNBC cell lines and patient tissues [24, 25] . Therefore it is worthy to investigate the role of GPER-signaling on AR-mediated proliferation of TNBC in absence of ER. Meanwhile, we have predicted the interaction of AR with mRNAs among the dysregulated mRNAs more than 2 fold-change, using the String prediction algorithm (http://string-db.org). Interestingly, GPER, one of the downregulated mRNAs, which has a relatively large fold change, is predicted to interact with AR, indicating a strong possibility as a downstream regulator of AR. To confirm the microarray results, we treated MDA-MB-231 and Hs578T cells with DHT and measured the expression of GPER at various time points by western blot analysis. As shown in Fig. 2B and Fig. 2C , DHT treatment induced a decrease of GPER protein expression in different time durations (24, 48 , or 72 h) in the two cells. Meanwhile, we detected GPER mRNA expression upon DHT treatment in the two cells by qRT-PCR analysis, and observed a robust decrease in the transcript levels of GPER compared with the control group (Fig. 2D , P < 0.05). Collectively, these data provide the evidence that DHT negatively regulates GPER expression in TNBC cells.
Activation of AR triggered by DHT inhibits GPER expression by binding to its promoter
To investigate the regulatory actions of AR on GPER expression, qRT-PCR analysis of GPER expression in the AR-transfected or AR-silenced cells was performed. A significant decrease of GPER mRNA levels was detected in the AR-transfected group of MDA-MB-231 and Hs578T cells, while an increase in the AR-silenced group (Fig. 3A and Fig. 3B ). To further assess the role of AR in DHT-mediated GPER expression, we knocked down AR in the 
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presence of DHT to examine whether AR affected DHT-mediated GPER expression. Western blot assay showed that AR deficiency significantly attenuated GPER suppression mediated by DHT (Fig. 3C and Fig. 3D ), suggesting the critical role of AR in mediating DHT-suppressed GPER signaling. Taken together, we propose that AR activation leads to the suppression of GPER.
To investigate the mechanisms of AR-induced proliferation in TNBC cells and whether AR directly interacted with GPER, we performed ChIP assay in MDA-MB-231 cells to immunoprecipitate cell chromatin with an anti-AR antibody and amplify the site located within the GPER promoter region. Our results illustrated that AR was strongly recruited at the promoter of GPER, located at -1509 to -1240 bp upstream of transcription start site (Fig.  3E, lane 7) . We observed that DHT administration enabled AR to bind to the region of GPER promoter located at -3000 to -2706 bp (Fig. 3E, lane 1) , indicating that DHT-induced AR activation enhanced the regulation of AR on the transcription of GPER. In brief, our results suggested that AR negatively regulated the expression of GPER through directly binding to its promoter as a transcription repressor. Moreover, DHT administration facilitated this procedure and made the binding more effectively.
The activation of GPER attenuates the stimulation effects of DHT on cellular proliferation
To evaluate the effects of GPER on DHT-induced cell growth, increasing concentrations of G-1, a well-known GPER agonist, were used to investigate the function of GPER in TNBC cells by MTT assay. Dose-dependent inhibition of cell growth was observed, and the treatment of G-1 at 1μM concentration resulted in a viability decrease of 45% and 35% in MDA-MB-231 and Hs578T cells, respectively (Fig. 4A ). In line with the previous studies [26] [27] [28] , the dose of 1μM G-1 was selected for further in vitro studies. Furthermore, we conducted knockdown assays in MDA-MB-231 cells to assess whether the inhibitory effects of G-1 depended on GPER activation. As shown in Fig. 4B , the silencing of GPER by shRNA in the presence of G-1 abolished the inhibitory effects of G-1 on cell viability of MDA-MB-231 cells. These data revealed that G-1 suppressed cellular proliferation of TNBC through the activation of GPER. Therefore, we hypothesized that the activation of GPER through G-1 could attenuate DHTstimulated proliferation of TNBC cells. Then MTT assays were performed to verify the role of GPER on DHT-induced motility of TNBC cells, it showed that addition of G-1 in the presence of DHT treatment blocked cell viability by 19% compared with DHT-alone group (Fig. 4C) . Consistently, colony formation assays exhibited that DHT treatment enhanced the ability of colony formation, while the activation of GPER by G-1 attenuated DHT-simulated colony formation by about 21% and 15.3%，respectively, in MDA-MB-231 and Hs578T cells (Fig.  4D) . Collectively, these results demonstrate that GPER is a key downstream regulator in the DHT-mediated process of cellular proliferation in TNBC cells.
AR-mediated GPER suppression is manifested in xenograft tumors and TNBC patients
Since we have demonstrated that GPER was involved in AR mediated oncogenic processes in TNBC cell lines, there was little direct evidence for the correlation of GPER and AR in vivo. Our previous studies have revealed that DHT treatment significantly accelerated the in vivo growth of MDA-MB-231 xenograft tumors in comparison with the control treatment [22] . In the present study, to assess the effects of DHT treatment on AR and GPER levels in the primary tumor xenografts, IHC staining analysis was conducted on the harvested xenogrft tumors obtained from our previous experiment as mentioned. Of note, an increase of AR expression and a reduction of GPER levels were found in paraffin-embedded tumor tissues obtained from DHT stimulated mice with respect to mice treated with vehicle ( Fig. 5A and Fig. 5B , P < 0.05). These data were consistent with the in vitro experimental model that DHT stimulated motility of TNBC cells and suppressed GPER expression through the activation of AR. Taken together, these data indicate that GPER, which could be suppressed by AR activation, is involved in the tumor growth of TNBC prompted by DHT.
To further provide clinical evidence for the role of AR and GPER in TNBC, we used an IHC staining analysis to assess the expression of AR and GPER in specimens from 165 TNBC patients using a tissue microarray. Representative staining is shown in Fig. 5C . 108 cases (65.5%) and 57 cases (34.5%) expressed GPER at high and low levels among the 165 tumor tissues, respectively (Table 3) . A significant negative correlation between AR and GPER expression was identified using the TNBC tissue-array (r = -0.282, P < 0.001) ( Table 3) . Taken together, our observations support the negative correlation between AR and GPER expression in tumor xenografts and TNBC patients.
Discussion
It is reported that AR plays a critical role in the progression of breast cancer cells, while its role in TNBC remains largely unknown. This present study showed that the expression of AR was positively associated with tumor size, lymph node metastasis and high-grade tumor in TNBC patients. Furthermore, we demonstrated that the AR agonist DHT promoted cellular proliferation of TNBC. In particular, we found out that DHT significantly inhibited expression of GPER through the activation of AR, which was mechanically confirmed by ChIP assay suggesting the directly binding of AR to the GPER promoter. Meanwhile, the over expression of GPER induced by the selective GPER agonist G-1 abolished AR-stimulated proliferative changes in TNBC cells. Our published study demonstrated that DHT treatment significantly promoted tumorigenesis in MDA-MB-231 xenografts mice. In the present study, we further observed the high expression of AR while low expression of GPER in xenograft tumors with DHT treatment. Consistent with our in vitro and in vivo studies, clinical data manifested that the expression of AR is negatively correlated with GPER expression while positively associated with tumor size, high-grade tumors, lymph node metastasis in 165 cases of TNBC patients.
AR, which can be activated by DHT, is widely expressed in various cancer types, involving in malignant progression. A recent review summarized conflicting data of preclinical researches on the complex role of AR in TNBC [29] . In our study, we detected that AR was highly expressed in about 35.8% of TNBC patients. Importantly, the expression level of AR was positively associated with tumor size, high-grade tumors and lymph node metastasis, indicating the association of AR expression with poor diagnosis. Our data were further supported by Jiang et al. [15] . who showed that AR expression was associated with decreased DFS in TNBC, but were not in agreement with a recent study, which indicated that AR expression was associated with favorable prognosis such as smaller tumor size, lower grade, and overall survival, particularly in the luminal breast cancer subtypes [30] . Nevertheless, emerging evidence implied intratumoral heterogeneity as a considerable issue that might influence the suitability of core biopsy. Diffuse staining, that is multiple punches taken for the one patient, may help evaluate the impact of intratumoral heterogeneity on the determination of AR and GPER expression in our experiment. Thus, further studies using a larger sample size with diffuse staining are needed to confirm these data.
As a member of nuclear receptors, AR mediates the biological process of cell cycle regulation and cell proliferation. In a ligand-independent manner, AR is located in the cytoplasm and forms a complex with heat shock protein. While in a ligand-dependent manner AR binds with DHT, AR homodimer will then translocate to nuclear and interact with androgen responsive elements to regulate transcription of downstream genes [31] . Here, we reported that the activation of AR via DHT exhibits the proliferative effects on TNBC cell lines. Actually, our results are consistent with the previous observations that AR drove tumor progression in some subtypes of TNBC models [32, 33] , as well as in AR+/ER-breast cancer cells [34, 35] . Meanwhile, some ER-positive BC cell lines, such as MCF-7 and MDA-MB-453, were growth-stimulated by androgens and inhibited by anti-androgens [17, 36] . In particular, AR expression has also been shown to influence neoadjuvant chemotherapy efficacy in the GeparTrio phase III study [37] . Nevertheless there exist some controversial studies suggesting that AR signaling antagonized the growth stimulatory effect of ER signaling in ER-positive breast cancer [33, 38] . Additionally, Tilley and colleagues demonstrated that two steroidal androgens inhibited proliferation in AR-positive breast cancer cell lines [39] . Owing to multiple players involved in TNBC, the complex role of AR remains elusive. Our results confirmed a proliferative role of AR in TNBC cells. Thus, further study is needed to confirm these data.
G-protein coupled estrogen receptor (GPER), a member of G-protein coupled receptor (GPCR), has been reported to modulate the progression of a variety of cancer types such as ovarian, endometrial, and breast cancers [14, 40] . Previous researches showed that GPER regulated the activities of epidermal growth factor receptors (EGFRs), mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling pathways [41, 42] . In this study, we conducted a microarray to explore the upstream regulator of AR. Interestingly, we observed a significant reduction of GPER level after DHT treatments. This is further confirmed that DHT suppressed GPER expression through the activation of AR. Further in vitro researches illustrated that activation of GPER through G-1 attenuated DHT-induced proliferation. Coincidentally, our current data are consistent with another study indicating that G-1 inhibited the in vivo growth and invasive potential of TNBC [43] . Consistent to the in vitro studies, the negative correlation of AR and GPER was confirmed in patient tissues and nude mouse xenografts. To date this report is the first time to illustrate the molecular events of GPER involved in AR-mediated pathway and elucidate the negative correlation between AR and GPER in TNBC patients.
As AR acts as transcription factor, we determined whether AR directly interacts with the region of GPER promoter. The direct interaction was confirmed by ChIP analysis, showing that AR occupied the promoter region of GPER. The transcription of GPER is negatively modulated through direct binding of AR to its promoter. We propose that AR occupies the Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry promoter region of GPER and competitively blocks the binding of the positive regulators to GPER promoter, ultimately leading to the down-regulation of GPER. Furthermore, DHT enhanced the inhibitory effects of AR on the transcription of GPER. Collectively, these results suggest that androgen-activated AR may suppress GPER expression, eliciting tumor stimulative actions on TNBC.
Conclusion
We report for the first time, that activation of AR via DHT may promote proliferation of TNBC through down regulation of GPER. Furthermore, our clinical data demonstrate that the expression of AR is negatively associated with GPER while positively associated with tumor size, lymph node metastasis and high-grade tumor in TNBC patients. This paper provides the rationale and data for the potential target therapy of AR and GPER in TNBC in future. Thus, further studies are needed to confirm our current findings and develop a potential strategy to treat TNBC clinically.
